The Global and National Burden of Chronic Kidney Disease Attributable to Ambient Fine Particulate Matter Air Pollution: a Modelling Study
Overview
Affiliations
Introduction: We aimed to integrate all available epidemiological evidence to characterise an exposure-response model of ambient fine particulate matter (PM) and the risk of chronic kidney disease (CKD) across the spectrum of PM concentrations experienced by humans. We then estimated the global and national burden of CKD attributable to PM.
Methods: We collected data from prior studies on the association of PM with CKD and used an integrative meta-regression approach to build non-linear exposure-response models of the risk of CKD associated with PM exposure. We then estimated the 2017 global and national incidence, prevalence, disability-adjusted life-years (DALYs) and deaths due to CKD attributable to PM in 194 countries and territories. Burden estimates were generated by linkage of risk estimates to Global Burden of Disease study datasets.
Results: The exposure-response function exhibited evidence of an increase in risk with increasing PM concentrations, where the rate of risk increase gradually attenuated at higher PM concentrations. Globally, in 2017, there were 3 284 358.2 (95% UI 2 800 710.5 to 3 747 046.1) incident and 122 409 460.2 (108 142 312.2 to 136 424 137.9) prevalent cases of CKD attributable to PM, and 6 593 134.6 (5 705 180.4 to 7 479 818.4) DALYs and 211 019.2 (184 292.5 to 236 520.4) deaths due to CKD attributable to PM. The burden was disproportionately borne by low income and lower middle income countries and exhibited substantial geographic variability, even among countries with similar levels of sociodemographic development. Globally, 72.8% of prevalent cases of CKD attributable to PM and 74.2% of DALYs due to CKD attributable to PM were due to concentrations above 10 µg/m, the WHO air quality guidelines.
Conclusion: The global burden of CKD attributable to PM is substantial, varies by geography and is disproportionally borne by disadvantaged countries. Most of the burden is associated with PM levels above the WHO guidelines, suggesting that achieving those targets may yield reduction in CKD burden.
Vanholder R, Be A, de Barbieri I, Gallego D, Fontana M, Faure M Clin Kidney J. 2025; 18(3):sfaf005.
PMID: 40052167 PMC: 11883230. DOI: 10.1093/ckj/sfaf005.
Lu M, Zhan Z, Li D, Chen H, Li A, Hu J Redox Biol. 2025; 80:103518.
PMID: 39891958 PMC: 11836507. DOI: 10.1016/j.redox.2025.103518.
Kou Y, Du S, Du W, Ye W, Yang Y, Qin L Front Public Health. 2024; 12:1372156.
PMID: 39618951 PMC: 11604608. DOI: 10.3389/fpubh.2024.1372156.
Harnessing Evolution and Biomimetics to Enhance Planetary Health: Kidney Insights.
Stenvinkel P, Shiels P, Kotanko P, Evenepoel P, Johnson R J Am Soc Nephrol. 2024; 36(2):311-321.
PMID: 39607684 PMC: 11801751. DOI: 10.1681/ASN.0000000582.
Chen J, Liu H, Li G, Bai L, Jiang Y, Wang J Environ Health (Wash). 2024; 2(8):553-562.
PMID: 39474284 PMC: 11504634. DOI: 10.1021/envhealth.4c00004.